Dr. Matthew Galsky:The CheckMate 274 study meticulously explored disease-free survival (DFS) as its cornerstone, encompassing a broad spectrum of patients and highlighting the nuanced benefits in those with high PD-L1 expression. While overall survival (OS) emerges as a critical secondary endpoint, ...
Dr. Matthew Galsky:The CheckMate 274 study meticulously explored disease-free survival (DFS) as its cornerstone, encompassing a broad spectrum of patients and highlighting the nuanced benefits in those with high PD-L1 expression. While overall survival (OS) emerges as a critical secondary endpoint, ...
Moreover, a final evaluation of HRQoL in relation to efficacy in CheckMate 274 should consider data for overall survival, which are not yet available. Limitations of the present study include assessment of HRQoL in <50% of patients from week 31 onward, largely because of patients discontinuing ...
An integrated, comprehensive partitioned survival analysis describes how patients spend overall survival (OS) time, on/off treatment, with/without toxicity. Previous analysis of first-line (1L) nivolumab (NIVO) + ipilimumab (IPI) for aRCC in CheckMate 214 showed treatment-free survival (TFS) ...
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial Results from phase 2 and 3 trials in patients with advanced melanoma have shown significant improvements in the ...
The trial also includes several secondary safety and efficacy endpoints, including overall survival (OS). The study is ongoing to assess the second dual primary endpoint of PFS in patients receiving Opdivo plus Yervoy compared to Opdivo alone across all l...
Background Nivolumab (NIVO) + ipilimumab (IPI) combination demonstrated improved overall survival (OS) benefits vs chemotherapy as first-line treatment for advanced NSCLC in both tumor programmed death ligand 1 (PD-L1) expression ≥ 1% and < 1% in CheckMate 227. CheckMate 817 is a multi-cohort...
Phase 2 CheckMate 069 Study Suggests Nivolumab Plus Ipilimumab May Improve Overall Survival in MelanomaJonathan GoodmanMPhilOncology Editor
Figure 1. Overall survival curves of Checkmate-901 trial. The identification of potential biomarkers of complete responses in the metastatic setting, like inherent platinum sensitivity with HRR pathway deficiency or ERCC2 mutations (as seen in the neoadjuvant setting), would aid in more effective pa...